Key Slides: Individualizing Treatment Recommendations for Patients With Hepatitis B Based on EASL Guidance

Review key data and EASL guideline recommendations on individualizing treatment for patients with HBV, including patients with renal or bone disease and pregnant women.
Francesco Negro, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 274 KB
Released: May 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Commentary from Nancy Reau on HDV and HBV

Nancy Reau, MD Released: July 22, 2021

Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)

Robert G. Gish, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Tarik Asselah: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Tarik Asselah, MD, PhD Released: July 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue